At Keva Health, we understand the challenges of managing Idiopathic Pulmonary Fibrosis (IPF). Our advanced remote patient monitoring program uses devices like pulse oximeters and spirometers to track oxygen levels and lung function between office visits, ensuring continuous care and timely interventions.
The platform monitors breathlessness, symptom progression, oxygen use, and medication adherence with real-time alerts—helping you gain deeper insights, act early, and support better long-term disease management from anywhere.
With Keva Health’s program, patients can manage their symptoms more proactively, with personalized insights and seamless care coordination.
With IPF monitoring on Keva365, patients record breathlessness, cough, and flare-ups daily to build a complete picture of trends over time.
Access to real-time notifications about any changes helps patients respond to issues quickly.
Keva365 allows patients to share their health data with your care team, supporting timely decisions and more personalized IPF management.
Track your spirometer readings and oxygen levels to stay on top of your lung function and detect early signs of decline.
Get access to your remote patient monitoring report, then share it with your physician to create your personalized care plan.
Patients may access the platform and get personalized tips at anytime.
Fill out this form to request more information or contact us! We can get in touch with your doctor to set up the program.
Keva365 is a Physician’s tool for IPFs management and monitoring optimization in between visits.
Our HIPAA-compliant and secured SaaS platform allows you to collect patient data in between clinic visits.
Bluetooth devices (pulse oximeter and spirometer) allow patients to monitor respiratory health.
Treatment pathway decision making for patients and their stratification through workflows made easy.
Get regular reports to track patient progress, manage care between visits, and use customizable alerts to save time while delivering quality care.
Idiopathic Pulmonary Fibrosis (IPF) is a condition characterized by progressive scarring of lung tissue, making breathing increasingly difficult. It is the most common type of lung fibrosis and has no cause. Scarring causes stiffness in the lungs and makes it difficult to breathe. Persistent dry coug, shortness of breath, unexplained weight loss, fatigue, aching in muscles and joints may be signs of IPF.
IPF often progresses gradually, and without consistent monitoring, subtle changes in lung function or oxygen levels can go unnoticed until they significantly impact daily life. Continuous symptom tracking, lung function monitoring, and medication adherence are critical to managing the disease effectively.
No money or other consideration is being solicited, and if sent in response, will not be accepted. No offer to buy the securities can be accepted and no part of the purchase price can be received until the offering statement is filed and only through an intermediary’s platform. An indication of interest involves no obligation or commitment of any kind. “reserving” securities is simply an indication of interest.